BioStock: SynAct advances pipeline and extends runway to 2027
Following a year of continued scientific and operational advancements, SynAct Pharma’s Q3 report outlines developments in the RESOLVE program in rheumatoid arthritis and ongoing preparations for new clinical activities across its macrophage-targeting pipeline. The report also confirms a financial runway extending into 2027. BioStock reached out to CEO Jeppe Øvlesen for a comment on the company’s clinical development and outlook for the coming year.
Read the full interview at biostock.se:
SynAct strengthens pipeline and extends financing to 2027
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/